By William Downey, Cindy Liu and Dr Jennifer Hartigan A recent report examines the trends in utilisation of compound libraries, as well as the impact of profiling on the size of screening decks. The drivers for choosing between large or focused libraries may be different,… Read More
By Dr Mikael Kubista Quantitative real-time PCR is becoming mature technology for the quantification of nucleic acids. It is spreading wide outside its original use in the research laboratories, becoming preferred technology for a range of applications, many that require specialised so lutions and adaptations. Integration with pre-analytical steps and… Read More
Design Of Experiments: Useful statistical tool in assay development or vendor disconnect By Dr John Comley The use of design of experiments (DOE) in assay development (AD) has the potential to speed up assay optimisation (ie reduce assay development bottlenecks) and to facilitate a more thorough evaluation of… Read More
Free Online Resources Enabling Crowd-Sourced Drug Discovery By Dr Antony J. Williams, Valery Tkachenko, Dr Chris Lipinski, Professor Alexander Tropsha and Dr Sean Ekins The availability of freely accessible online resources to enable and support drug discovery has blossomed in recent years. The PubChem platform is now accompanied… Read More
Current and Emerging Trends in Cell-Based Assays – Roundtable In 2009 Drug Discovery World hosted a collegial-style roundtable discussion on the present and emerging developments in this exciting and now, fundamental area of drug discovery. The participants are recognised to be thought leaders… Read More
Innovations In Drug Discovery Technology By Dr Al Kolb Technology has been a major driver of advances in drug discovery. Automation, nanofluidics, imaging, software and assay technologies have played a major role in getting better data, faster. Is drug discovery at such an advanced… Read More
Maximising the impact of technologies on drug discovery through portfolio management By Charles S. Dormer, Dr Mark Beggs, Dr Lynn Brennan and Roanna London The opportunities to invest in new technologies in drug discovery are broad and extensive. Knowing where to place your investment and ensuring return… Read More
Integrating Computational Methods and Drug Discovery – Avoiding pitfalls in chemical space By Alexandre Ismail and Professor Philippe Manivet The immensity of the task in discovering suitable molecules for development among the vast number which are theoretically available is well stated. With 90% of potentially efficacious compounds… Read More
Multiplexing for biological relevance in high throughput screening By William P. Downey, Dr Jennifer Hartigan and Cindy Liu The multiplexed assay is a technique used increasingly in high throughput screening (HTS) labs to study the complex environment of a target, according to HighTech Business Decisions’ (HTBD) industry… Read More
By Dr John Comley After nearly 15 years of challenging maturity 1536 plate adoption (particularly in primary screening), finally appears to have taken hold. There is now available a broad range of 1536 plate types; an ever expanding variety of tools that make… Read More
Himarnessing fragment-based drug discovery at CRT By Dr Andrew P Turnbull and Dr Martin E Swarbrick In the past decade, fragment-based drug discovery (FBDD) has gained increasing popularity in the pharmaceutical industry as a powerful alternative and complement to traditional high-throughput screening (HTS) as a source of preliminary… Read More
Structure-Based Drug Design – Will crystallisation ‘chaperones’ make all proteins crystallisable? By Dr Chun-wa Chung Macromolecular x-ray crystallography is usually an integral part of small molecule drug discovery for soluble targets. Recent advances in the crystallography of membrane proteins, such as ion channels and G-protein-coupled receptors, have… Read More
Automation Of Solid/Powder Dispensing: Much needed, but cautiously used! By Dr John Comley This article investigates solid/powder dispensing in pharma and biotech, examines where it is most used, whether there exists a need to apply automation and what is motivating its wider use today. It reveals how concerns… Read More
Overcoming the Limitations of Chemical Structure By Dr Andy Vinter, Dr Steve Gardner and Dr Sally Rose The pharmaceutical business has been profoundly hampered by a ubiquitous and unexpected obstacles; the way it draws its chemical compounds. Scientists, patent agents and business decision makers from R&D, safety,… Read More
Modular Automation for Screening: A cost/benefit analysis By Dr Jonathan Wingfield Cost is now a key driver for pharmaceutical companies and in many respects shapes the capital, revenue and resource decisions that have to be made during the drug discovery process. Where companies are resource rich, the need… Read More
Letting the Target Determine your Compound Acquisition Strategy By Dr John Harris With compound libraries likely to remain the cornerstone of hit and lead discovery for the foreseeable future, this paper seeks to summarise current and future approaches to optimal library design and compound acquisition, using examples… Read More